Novatek is pleased to have it’s Stability Management Software, Nova-Stability chosen for Allena Pharmaceuticals in Massachusetts, USA. Nova-Stability offers powerful functionality and is backed by hundreds of user requirements. Our system incorporates the in-depth knowledge of numerous experts in the best quality practices driving higher adoption and greater operational efficiency to our clients.
To learn more, or request a demo of Nova-Stability, contact us today at sales@ntint.com.
About Allena Pharmaceuticals
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
